Compare Torrent Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs CIPLA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA CIPLA TORRENT PHARMA/
CIPLA
 
P/E (TTM) x 55.1 23.9 230.8% View Chart
P/BV x 6.6 2.4 270.8% View Chart
Dividend Yield % 0.8 0.7 117.7%  

Financials

 TORRENT PHARMA   CIPLA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
CIPLA
Mar-19
TORRENT PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,550678 228.6%   
Low Rs1,144484 236.4%   
Sales per share (Unadj.) Rs354.7198.2 178.9%  
Earnings per share (Unadj.) Rs40.118.5 216.3%  
Cash flow per share (Unadj.) Rs64.235.0 183.6%  
Dividends per share (Unadj.) Rs14.003.00 466.7%  
Dividend yield (eoy) %1.00.5 201.3%  
Book value per share (Unadj.) Rs273.1186.3 146.6%  
Shares outstanding (eoy) m169.22805.70 21.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.82.9 129.6%   
Avg P/E ratio x33.631.4 107.2%  
P/CF ratio (eoy) x21.016.6 126.3%  
Price / Book Value ratio x4.93.1 158.1%  
Dividend payout %34.916.2 215.7%   
Avg Mkt Cap Rs m227,897468,031 48.7%   
No. of employees `00014.722.6 64.9%   
Total wages/salary Rs m11,35328,565 39.7%   
Avg. sales/employee Rs Th4,083.07,053.1 57.9%   
Avg. wages/employee Rs Th772.31,261.5 61.2%   
Avg. net profit/employee Rs Th461.3659.1 70.0%   
INCOME DATA
Net Sales Rs m60,021159,710 37.6%  
Other income Rs m2,9884,766 62.7%   
Total revenues Rs m63,009164,475 38.3%   
Gross profit Rs m13,49330,973 43.6%  
Depreciation Rs m4,08613,263 30.8%   
Interest Rs m3,0851,684 183.2%   
Profit before tax Rs m9,31020,791 44.8%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5295,695 44.4%   
Profit after tax Rs m6,78114,924 45.4%  
Gross profit margin %22.519.4 115.9%  
Effective tax rate %27.227.4 99.2%   
Net profit margin %11.39.3 120.9%  
BALANCE SHEET DATA
Current assets Rs m52,623124,266 42.3%   
Current liabilities Rs m52,02237,715 137.9%   
Net working cap to sales %1.054.2 1.8%  
Current ratio x1.03.3 30.7%  
Inventory Days Days12091 132.0%  
Debtors Days Days7695 80.4%  
Net fixed assets Rs m85,016105,190 80.8%   
Share capital Rs m8461,611 52.5%   
"Free" reserves Rs m45,376148,511 30.6%   
Net worth Rs m46,222150,123 30.8%   
Long term debt Rs m41,11538,301 107.3%   
Total assets Rs m142,432239,633 59.4%  
Interest coverage x4.013.3 30.1%   
Debt to equity ratio x0.90.3 348.6%  
Sales to assets ratio x0.40.7 63.2%   
Return on assets %6.96.9 99.9%  
Return on equity %14.79.9 147.6%  
Return on capital %14.211.8 119.9%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58057,410 25.4%   
Fx outflow Rs m3,60019,041 18.9%   
Net fx Rs m10,98038,368 28.6%   
CASH FLOW
From Operations Rs m8,94216,911 52.9%  
From Investments Rs m-47,070-16,687 282.1%  
From Financial Activity Rs m34,174-3,487 -980.0%  
Net Cashflow Rs m-3,655-3,451 105.9%  

Share Holding

Indian Promoters % 71.5 16.0 446.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 7.0 12.2 57.5%  
FIIs % 12.6 23.7 53.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 8.8 26.2 33.6%  
Shareholders   26,511 161,166 16.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  WOCKHARDT  AUROBINDO PHARMA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Nov 11, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS